leader in developing an oral vaccine for COVID-19 that would make it significantly easier to vaccinate the world, notes biotech sector expert John McCamant, editor of The Medical Technology Stock Letter. Could an oral vaccine be the Holy Grail in fighting a pandemic? A pill can be stored at room temperature, no freezer/refrigeration required, given anywhere, no syringe/nurse required, provides mucosal immunity, stops virus before entering bloodstream. The company's unique vaccine pill should garner both corporate and government partnerships around the world as the easy to manufacture, off the shelf oral vaccine addresses many of the shortcomings of 1st generation vaccines. VXRT’s Phase II trial of VXA-CoV2-1, encoding both the S and the N proteins, is expected to start mid-year. Manufacturing of vaccines is currently underway at the company’s manufacturing partner, and their own GMP facility. VXRT is also evaluating additional manufacturing partners both in the U.S. and abroad as we experience unprecedented global demand for both vaccine manufacturing and the raw materials. Phase I/II studies of two S-only vaccine constructs targeting different variants are planned to begin in 3Q 2021. Boosting studies with previously vaccinated or infected subjects are also planned for 2H 2021. Trials in India and Latin America are expected to initiate in 2021. In our view, the company's oral vaccine technology will be needed to combat COVID-19 and its variants in the coming years. We also believe the recent rapid advancement of COVID-19 vaccines and their huge impact illustrate the potential for VXRT’s other vaccine candidates, including Noravirus and the seasonal flu all of which could be combined into one pill. Vaxart — which has risen 24% since the start of the year — is a currently rated a "buy" under $15 with a target price of $30 per share. Subscribe to The Medical Technology Stock Letter here…
Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantly easier to vaccinate the world, notes biotech sector expert John McCamant, editor of The Medical Technology Stock Letter.
Could an oral vaccine be the Holy Grail in fighting a pandemic? A pill can be stored at room temperature, no freezer/refrigeration required, given anywhere, no syringe/nurse required, provides mucosal immunity, stops virus before entering bloodstream.
The company's unique vaccine pill should garner both corporate and government partnerships around the world as the easy to manufacture, off the shelf oral vaccine addresses many of the shortcomings of 1st generation vaccines.
VXRT’s Phase II trial of VXA-CoV2-1, encoding both the S and the N proteins, is expected to start mid-year. Manufacturing of vaccines is currently underway at the company’s manufacturing partner, and their own GMP facility.
VXRT is also evaluating additional manufacturing partners both in the U.S. and abroad as we experience unprecedented global demand for both vaccine manufacturing and the raw materials.
Phase I/II studies of two S-only vaccine constructs targeting different variants are planned to begin in 3Q 2021. Boosting studies with previously vaccinated or infected subjects are also planned for 2H 2021. Trials in India and Latin America are expected to initiate in 2021.
In our view, the company's oral vaccine technology will be needed to combat COVID-19 and its variants in the coming years.
We also believe the recent rapid advancement of COVID-19 vaccines and their huge impact illustrate the potential for VXRT’s other vaccine candidates, including Noravirus and the seasonal flu all of which could be combined into one pill.
Vaxart — which has risen 24% since the start of the year — is a currently rated a "buy" under $15 with a target price of $30 per share.
G
Positive reasons why the stock price very well could increase before the current patient trials are finished. #1 J and J partnership is announced.
#2 Funding by the government is announced
#3 all litigation is settled without any liabilities towards Vaxart
#4 oral tablet processing licensing agreements with other pharmaceutical companies
#5 manufacturing and or distribution partnerships and or contracts.
Each of these items will add positively to a rise in the stock price if they occur before any current patient trials are completed.
Stock value effects the price, market capitalization amount and additional acquisition of shares driving the price upwards.
For these reasons I am very bullish on Vaxart as well as many others on this message board.
More information this coming Monday.
G
Good morning, now that the press conference is over and he said exactly what i told you he'd say "forward looking... potential..." and STILL no set date for a phase 2 beginning. I think its time for the baggers to make excuses on why they werent REALLY wrong again, and that everything is going exactly as expected.
BTW for those keeping track vaccines world wide are as follows: 51 in Phase 1 37 Phase 2 31 Phase 3 8 limited approval for use 8 Approved for full use
(vaxart is considered phase 1 BTW since they have no date for phase 2) thats 84 vaccines further along than vaxart.. "But we have a pill" Yeah hit me up when its approved, THEN you have a pill.
I see your big 10 cent short squeeze is gone in PM. "PM doesnt matter (when its against vaxart)" Did you sell before now? then it matters. if you cant sell for the closing price yesterday, then its not the price anymore. Thats how it works.
I think i covered everything preemptively besides trailer park Dog with his moms joint credit card making some kind of reference to me having a job, and David saying something about longs never providing proof. Wayne making a prediction of 10 by friday? and a batch of other id10ts, still pumping the 3.2 billion dollars for antiviral (NOT VACCINE) that vaxart will not get a dime of.
J
If clinical trials of a pill vaccine are successful, there are many benefits.
Ease of distribution, storage and inoculation reduces labor costs, allowing Vaxart to demand higher drug prices from the government.
Higher drug prices can connect more vaccine producers to quickly increase production.
In addition, because it is easy to inoculate, a low-dose vaccine with fewer side effects can be mass-produced and administered to young and underdeveloped countries.
Low-dose vaccines are likely to be very useful in developing countries with a low mortality rate due to their young population.
I do want to remind everyone including the shorts that this is a CONFERENCE. A conference is NOT a medium for releasing PRs or news. It is however a forum to make presentations to their peers consisting of immunologists and scientists!
M
News of federal grant anytime and stock will double . Oral vaccine pioneer
R
Vaxart has moved to wave 3 of the Elliot Wave Cycle. This is considered a bullish trend and usually is the most powerful in the 5 wave trend.
T
VXRT has a $14.50 price target estimate and another analyst upgraded VXRT to an $18 price target estimate. Anything wrong with a 100% return on today's stock price?!?! 📈
s
Yahoo is showing a block trade of 4.68 millions shares on a down tick at 1:46PM. Probably will be hard to borrow that much to short again.
f
hold your shares, don't sell for a few bucks/K, the future of a unique pill form for vaccines is very interesting.
C
Vaxart — which has risen 24% since the start of the year — is a currently rated a "buy" under $15 with a target price of $30 per share
Vaxart pill is a must for health of the nation and the world. US Government will provide massive funding. "Delta Variant Will Likely Become Dominant Covid-19 Strain In US, CDC Chief Says"
A
why would you short a $7 stock where news and or hype can send it skyrocketing? I did puts on bynd recently w huge gain, but would never do puts on vxrt unless I sold after a huge gain where there was no new news. vxrt tends to recycle news as of late. shorting or putting vxrt otherwise pays off very little for the money and effort. You got crushed by vxrt in the past and just dont know how to move on w/ your sad life as seen on the vxrt board.
M
•18$ Price upgrade by Piper Sandlers •Insiders buying up a ton of shares • $3.5b funding for covid treatment etc
A
It's Triple-Witching, expiration of Index Options, Index Futures and Stock Options; a day where profits are unwound and portfolios are realigned. VXRT is no exception. Traders that understand this day, take early profits if in the green there is an 85% probability those profits will erode by day end… if in the red a good buying opportunity. With VXRT many day traders have a chance to add another 12% plus to their day trades. Sold at $8.85 this morning .... just finished buying back 13% more with those proceeds. That’s how I get longer and stronger. I will be ready for next week. Happy Investing!
Could an oral vaccine be the Holy Grail in fighting a pandemic? A pill can be stored at room temperature, no freezer/refrigeration required, given anywhere, no syringe/nurse required, provides mucosal immunity, stops virus before entering bloodstream.
The company's unique vaccine pill should garner both corporate and government partnerships around the world as the easy to manufacture, off the shelf oral vaccine addresses many of the shortcomings of 1st generation vaccines.
VXRT’s Phase II trial of VXA-CoV2-1, encoding both the S and the N proteins, is expected to start mid-year. Manufacturing of vaccines is currently underway at the company’s manufacturing partner, and their own GMP facility.
VXRT is also evaluating additional manufacturing partners both in the U.S. and abroad as we experience unprecedented global demand for both vaccine manufacturing and the raw materials.
Phase I/II studies of two S-only vaccine constructs targeting different variants are planned to begin in 3Q 2021. Boosting studies with previously vaccinated or infected subjects are also planned for 2H 2021. Trials in India and Latin America are expected to initiate in 2021.
In our view, the company's oral vaccine technology will be needed to combat COVID-19 and its variants in the coming years.
We also believe the recent rapid advancement of COVID-19 vaccines and their huge impact illustrate the potential for VXRT’s other vaccine candidates, including Noravirus and the seasonal flu all of which could be combined into one pill.
Vaxart — which has risen 24% since the start of the year — is a currently rated a "buy" under $15 with a target price of $30 per share.
Subscribe to The Medical Technology Stock Letter here…
https://www.moneyshow.com/articles/tptp2021-56825/top-picks-mid-year-updates-vaxart/
John McCamant
Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantly easier to vaccinate the world, notes biotech sector expert John McCamant, editor of The Medical Technology Stock Letter.
Could an oral vaccine be the Holy Grail in fighting a pandemic? A pill can be stored at room temperature, no freezer/refrigeration required, given anywhere, no syringe/nurse required, provides mucosal immunity, stops virus before entering bloodstream.
The company's unique vaccine pill should garner both corporate and government partnerships around the world as the easy to manufacture, off the shelf oral vaccine addresses many of the shortcomings of 1st generation vaccines.
VXRT’s Phase II trial of VXA-CoV2-1, encoding both the S and the N proteins, is expected to start mid-year. Manufacturing of vaccines is currently underway at the company’s manufacturing partner, and their own GMP facility.
VXRT is also evaluating additional manufacturing partners both in the U.S. and abroad as we experience unprecedented global demand for both vaccine manufacturing and the raw materials.
Phase I/II studies of two S-only vaccine constructs targeting different variants are planned to begin in 3Q 2021. Boosting studies with previously vaccinated or infected subjects are also planned for 2H 2021. Trials in India and Latin America are expected to initiate in 2021.
In our view, the company's oral vaccine technology will be needed to combat COVID-19 and its variants in the coming years.
We also believe the recent rapid advancement of COVID-19 vaccines and their huge impact illustrate the potential for VXRT’s other vaccine candidates, including Noravirus and the seasonal flu all of which could be combined into one pill.
Vaxart — which has risen 24% since the start of the year — is a currently rated a "buy" under $15 with a target price of $30 per share.
#1 J and J partnership is announced.
#2 Funding by the government is announced
#3 all litigation is settled without any liabilities towards Vaxart
#4 oral tablet processing licensing agreements with other pharmaceutical companies
#5 manufacturing and or distribution partnerships and or contracts.
Each of these items will add positively to a rise in the stock price if they occur before any current patient trials are completed.
Stock value effects the price, market capitalization amount and additional acquisition of shares driving the price upwards.
For these reasons I am very bullish on Vaxart as well as many others on this message board.
More information this coming Monday.
I think its time for the baggers to make excuses on why they werent REALLY wrong again, and that everything is going exactly as expected.
BTW for those keeping track vaccines world wide are as follows:
51 in Phase 1
37 Phase 2
31 Phase 3
8 limited approval for use
8 Approved for full use
(vaxart is considered phase 1 BTW since they have no date for phase 2) thats 84 vaccines further along than vaxart..
"But we have a pill"
Yeah hit me up when its approved, THEN you have a pill.
I see your big 10 cent short squeeze is gone in PM.
"PM doesnt matter (when its against vaxart)"
Did you sell before now? then it matters. if you cant sell for the closing price yesterday, then its not the price anymore. Thats how it works.
I think i covered everything preemptively besides trailer park Dog with his moms joint credit card making some kind of reference to me having a job, and David saying something about longs never providing proof.
Wayne making a prediction of 10 by friday?
and a batch of other id10ts, still pumping the 3.2 billion dollars for antiviral (NOT VACCINE) that vaxart will not get a dime of.
Ease of distribution, storage and inoculation reduces labor costs, allowing Vaxart to demand higher drug prices from the government.
Higher drug prices can connect more vaccine producers to quickly increase production.
In addition, because it is easy to inoculate, a low-dose vaccine with fewer side effects can be mass-produced and administered to young and underdeveloped countries.
Low-dose vaccines are likely to be very useful in developing countries with a low mortality rate due to their young population.
https://stocksregister.com/2021/06/22/would-i-ever-invest-in-vaxart-inc-nasdaq-vxrt-at-any-point-in-time/
A conference is NOT a medium for releasing PRs or news.
It is however a forum to make presentations to their peers consisting of immunologists and scientists!
Oral vaccine pioneer
https://investorplace.com/2021/06/vxrt-stock-can-redditors-help-vaxart-power-higher/
"Delta Variant Will Likely Become Dominant Covid-19 Strain In US, CDC Chief Says"
•Insiders buying up a ton of shares
• $3.5b funding for covid treatment etc
Traders that understand this day, take early profits if in the green there is an 85% probability those profits will erode by day end… if in the red a good buying opportunity.
With VXRT many day traders have a chance to add another 12% plus to their day trades.
Sold at $8.85 this morning .... just finished buying back 13% more with those proceeds. That’s how I get longer and stronger. I will be ready for next week. Happy Investing!